Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of UQSC2 Vaccine in Healthy Adults
NCT05775887Phase 1Completed
- Sponsor
- The University of Queensland
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UQSC2 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The University of Queensland. Primary endpoints: Frequency, duration, and intensity of solicited local adverse events, Frequency, duration, and intensity of solicited systemic adverse events and 3 more. Started May 2023; status: completed.
02
Drugs
UQSC2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05775887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775887.